recombinant interleukin-11

Phase 2Protein / enzyme

recombinant interleukin-11 is one of 39 small molecule programs targeting Von Willebrand disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Breast CancerActive, not recruiting

Von Willebrand DiseasePhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Megace

Bristol-Myers Squibb

Preclinical

4 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Zinecard

CChildren's Oncology Group

Preclinical

2 6

recombinant interleukin-11

UUniversity of Pittsburgh

Phase 2

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Von Willebrand disease1 trial

Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

Completed·UUniversity of Pittsburgh·Phase 2·NCT00151125·12 enrolled

Breast Cancer1 trial

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00004157

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for recombinant interleukin-11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant interleukin-11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant interleukin-11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pittsburgh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Pittsburgh

recombinant interleukin-11

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Von Willebrand disease1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News